Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label trial with TMC125 [etravirine] as part of an ART [antiretroviral therapy] including TMC114/Rtv [darunavir/ritonavir] and an investigator-selected OBR [optimised background regimen] in HIV-1 infected subjects who participated in a DUET phase III trial (TMC125-C206 or TMC125-C216)

Next Previous
X
Search
Trial Profile

An open-label trial with TMC125 [etravirine] as part of an ART [antiretroviral therapy] including TMC114/Rtv [darunavir/ritonavir] and an investigator-selected OBR [optimised background regimen] in HIV-1 infected subjects who participated in a DUET phase III trial (TMC125-C206 or TMC125-C216)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etravirine (Primary) ; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms DUET
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 26 Jun 2012 EudraCT reports actual initiation date 3 Aug 2006.
    • 22 Jun 2012 Additional locations identified as reported by as reported by European Clinical Trials Database.
    • 10 Apr 2012 Actual patient number 322 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top